刘泽毅

（1）研究方向

1、早期肺癌表观遗传与细胞分子生物学

2、晚期肺癌新药筛选及耐药机制研究

（2）招生专业

临床医学-内科学-呼吸系病学

（3）招生类型

学术型博士、学术型硕士

（4）E-mail

liuzeyisuda@163.com；zeyiliu@suda.edu.cn

（5）导师简介

刘泽毅，中共党员，医学博士，研究员，博士生导师，现任苏州大学呼吸疾病研究所办公室主任，苏州大学附属第一医院呼吸系统疾病研究室副主任。先后入选江苏省第六期“333高层次人才”、江苏省十三五科教强卫工程“青年医学重点人才”和苏州市第七批“姑苏卫生人才”。作为项目负责人主持国家自然科学基金面上项目和青年项目各1项、其他省部级、市厅级课题多项。作为主要获奖人获得江苏省科技进步一等奖、二等奖各1项及教育部高等学校优秀成果二等奖1项。现担任中华医师协会呼吸医师分会研究工作委员会第一届委员会委员、海峡两岸医药卫生交流协会呼吸病学专业委员会肺癌学组委员、江苏省研究型医院学会肺结节与肺癌MDT委员会常务委员和江苏省预防医学会呼吸系统疾病预防与控制专业委员会委员。

（6）代表性论文

1. Gao L, Wang A, Chen Y, Cai X, Li Y, Zhao J, Zhang Y, Zhang W, Zhu J, Zeng Y, Liu Z, Huang JA.FTO facilitates cancer metastasis by modifying the m6A level of FAP to induce integrin/FAK signaling in non-small cell lung cancer. Cell Commun Signal. 2023 Nov 2;21(1):311.

2. Shen D, Zeng Y, Zhang W, Li Y, Zhu J, Liu Z, Yan Z, Huang JA. Chenodeoxycholic acid inhibits lung adenocarcinoma progression via the integrin α5β1/FAK/p53 signaling pathway.Eur J Pharmacol. 2022 May 15;923:174925.

3. Zhou J, Wang A, Cai T, Li Y, Du W, Zhang Y, Zhang R, Zhang W, Zhu J, Zeng Y, Huang JA, Liu Z. Integrin α3/α6 and αV are implicated in ADAM15-activated FAK and EGFR signalling pathway individually and promote non-small-cell lung cancer progression. Cell Death Dis. 2022 May 21;13(5):486.

4. Wang A, Yang W, Li Y, Zhang Y, Zhou J, Zhang R, Zhang W, Zhu J, Zeng Y, Liu Z, Huang JA. CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway.Cell Commun Signal. 2022 Jan 31;20(1):16. 

5. Zhang R, Zhang W, Zeng Y, Li Y, Zhou J, Zhang Y, Wang A, Lv Y, Zhu J, Liu Z, Huang JA. The regulation of CPNE1 ubiquitination by the NEDD4L is involved in the pathogenesis of non-small cell lung cancer.Cell Death Discov. 2021 Nov 6;7(1):336.

6. Zhu J, Cai T, Zhou J, Du W, Zeng Y, Liu T, Fu Y, Li Y, Qian Q, Yang XH, Li Q, Huang JA, Liu Z. CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer. J Exp Clin Cancer Res. 2021 Jun 9;40(1):192. 

7. Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang A, Du W, Zeng Y, Zhu J, Liu Z, Huang JA.  Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol. 2020 Dec 7;13(1):169. 

8. Du W, Zhu J, Zeng Y, Liu T, Zhang Y, Cai T, Fu Y, Zhang W, Zhang R, Liu Z, Huang JA. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway. Cell Death Differ. 2021 Apr;28(4):1284-1300. 

9. Cai T, Zhou J, Zeng Y, Du W, Zhang Y, Liu T, Fu Y, Huang JA, Qian Q, Zhu J, Ling C, Liu Z. EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells. J Exp Clin Cancer Res. 2020 May 11;39(1):84.

10. Ling C, Wang X, Zhu J, Tang H, Du W, Zeng Y, Sun L, Huang JA, Liu Z. MicroRNA-4286 promotes cell proliferation, migration, and invasion via PTEN regulation of the PI3K/Akt pathway in non-small cell lung cancer. Cancer Med. 2019 Jul;8(7):3520-3531.